Effects of Specific Antibodies against Streptococcus pneumoniae on Pharmacodynamic Parameters of β-Lactams in a Mouse Sepsis Model

• DOI: 10.1128/aac.46.5.1340-1344.2002
• Publication Date: 2002-07-27T10:09:01Z
• Authors: J. Casal; L. Aguilar; I. Jado; J. Yuste; M. J. Giménez; J. Prieto; A. Fenoll
• Keywords: Pharmacodynamics; Pneumococcal infections

ABSTRACT A dose-ranging study to investigate the in vivo effects of presence specific antibodies on efficacy β-lactam treatment sepsis caused by Streptococcus pneumoniae (non-β-lactam-susceptible serotype 6B isolate) was performed with a BALB/c mouse model. Hyperimmune serum obtained from mice immunized heat-inactivated strain. The rate mortality 100% nontreated animals absence antibodies. single injection one-half or one-quarter dilution hyperimmune produced 60 40% survival rates. In antibodies, minimal effective doses amoxicillin and cefotaxime that rates 100 80% were 25 50 mg/kg body weight (three times day for up six doses), respectively. These levels remained above MIC (Δ T > MICs) ≈30% dosing interval. When present (by administration serum), antibiotics 3.12 6.25 (≈8 lower), Δ MICs being approximately 3 5% interval cefotaxime, This combined pharmacodynamic effect offers possibilities can be used address penicillin resistance.